Rapastinel Approval Status
Rapastinel (GLYX-13) is a novel NMDA receptor modulator in clinical development as an intravenous adjunctive therapy for major depressive disorder (MDD).
Development Status and FDA Approval Process for rapastinel
|Mar 3, 2014||FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.